Effect of CD105, CA125 and CA724 levels by paclitaxel combined with cisplatin in patients with cervical cancer
10.3969/J.ISSN.1672-8270.2016.12.030
- VernacularTitle:血清可溶性CD105、糖类抗原CA125和CA724水平检测在宫颈癌联合化疗中的价值研究
- Author:
Fangmei FENG
;
Xiaoyong ZHU
- Keywords:
Cervical cancer;
Paclitaxel;
Cisplatin;
CD105;
CA125;
CA724
- From:
China Medical Equipment
2016;13(12):105-108
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the value of serum CD105, CA125 and CA724 levels in the treatment of cervical cancer with paclitaxel and cisplatin.Methods: A total of 42 patients with cervical cancer were randomly divided into observation group (n=21) and control group (n=21). The observation group was given intravenous infusion of paclitaxel 135 mg/m2, and intravenous infusion of cisplatin 60 mg/m2 after 3 hours. The control group was given only intravenous infusion of cisplatin, during the hydration and antiemetic drugs. They need 2 courses of chemotherapy, with each chemotherapy interval of 21 days. The levels of serum CD105, CA125 and CA724 before and after treatment were compared and analyzed.Results: The levels of CD105, CA125 and CA724 in the observation group were lower than those in the control group (t=19.119,t=22.493,t=15.46;P<0.05). There was a negative correlation between CD105, CA125 and CA724 levels and clinical efficacy (rs=-0.427,rs=-0.335,rs=-0.408;P<0.05).Conclusion: Paclitaxel combine with cisplatin in the treatment of cervical cancer has better clinical curative effect, and the mechanism is related to lower CD105, CA125 and CA724 levels.
